Showing 1041-1050 of 1161 results for "".
- “Dr. Robert Ritch Forum on Medicine of the Future” at World Ophthalmology Congress 2018https://modernod.com/news/dr-robert-ritch-forum-on-medicine-of-the-future-at-world-ophthalmology-congress-2018/2480090/Robert Ritch, MD, Distinguished Chair in Ophthalmology at New York Eye and Ear Infirmary of Mount Sinai will host the “Robert Ritch Forum on Medicine of the Future” at the World Ophthalmology Congress 2018 (WOC2018) in Barcelona, Spain. This is the first time WOC is dedicating an entire fo
- FDA Commissioner Scott Gottlieb Proposes Modernization of FDA’s Drug Review Officehttps://modernod.com/news/fda-commissioner-scott-gottlieb-provides-statement-on-proposed-modernization-of-fdas-drug-review-office/2480120/FDA Commissioner Scott Gottlieb, MD, released a statement Monday outlining the agency’s position on a proposed modernization of FDA’s Drug Review Office. The statement reads: “Scientific and medical advances are giving the FDA more opportunities to more fully address diseases a
- Ivantis Announces Results of Comparative MIGS Clinical Trialhttps://modernod.com/news/ivantis-announces-results-of-comparative-migs-clinical-trial/2480238/Ivantis, developer of the Hydrus Microstent, announced the 12-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS). Results from the study will be presented by David Chang, MD, clinical professor of Ophthalmology at the University of California, San Francisco, during
- SERI Lugano: ParaCel Riboflavin Selected by FDA for Epi-on Cross-Linking for Keratoconushttps://modernod.com/news/seri-lugano-paracel-riboflavin-selected-by-fda-for-epi-on-cross-linking-for-keratoconus/2480255/The Switzerland Eye Research Institute has announced that the breakthrough transepithelial riboflavin formulation known as ParaCel, and based on the research of its CEO and Founder Roberto Pinelli, MD, has been selected among many others by the FDA for an epithelium-on corneal collagen cross-link
- Topcon Receives FDA Clearance for OCT Angiography on the Maestro2 Systemhttps://modernod.com/news/topcon-receives-fda-clearance-for-octa-on-the-maestro2-system/2482439/Topcon Healthcare has received FDA 510(k) clearance for OCT angiography (OCTA) on the company’s Maestro2 robotic OCT color fundus camera system. According to Topcon, the Maestro2 offers 3×3-mm, 4.5×4.5-mm, and 6x6-mm OCTA scans, which provide the flexibility to le
- FDA Clears Alcon's Unity Vitreoretinal-Cataract System and Standalone Cataract Systemhttps://modernod.com/news/fda-clears-alcons-unity-vitreoretinal-cataract-system-and-unity-standalone-cataract-system/2482329/Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) have received FDA 510(k) clearance. The new devices are the first to be introduced from Alcon’s Unity portfolio and represent Alcon's next generation of e
- Bio-Tissue to Present Webinar in 3-D Showcasing New Treatment Regimen to Diagnose and Treat Mechanical Dry Eyehttps://modernod.com/news/bio-tissue-to-present-webinar-in-3-d-showcasing-new-treatment-regimen-to-diagnose-and-treat-mechanical-dry-eye/2479188/Bio-Tissue announced today that it will present a special 3-D webinar on Wednesday, May 19, 2021, from 8:30 pm to 9:30 pm EDT, hosted by Neel Desai, MD, who will demonstrate his novel surgical technique known as Reservoir Restoration to treat Mechanical Dry Eye (MDE). He will also discuss how to
- Eyenuk Secures the First European Union MDR Certification for Autonomous AI Detection of DR, AMD, and Glaucomahttps://modernod.com/news/eyenuk-secures-the-first-european-union-mdr-certification-for-autonomous-ai-detection-of-diabetic-retinopathy-amd-and-glaucoma/2481377/Eyenuk has been approved to market its EyeArt AI eye screening system in the European Union for the new uses of detecting age-related macular degeneration (AMD) and glaucomatous optic nerve damage. The EyeArt AI system (version 3.0) has been granted a new European Commiss
- Samsung Bioepis to Regain European Commercial Rights for Ophthalmology Biosimilars from Biogenhttps://modernod.com/news/samsung-bioepis-to-regain-european-commercial-rights-for-ophthalmology-biosimilars-from-biogen/2484299/Samsung Bioepis has entered into an Asset Purchase Agreement (APA) with Biogen concerning the transfer of two ophthalmology assets: Byooviz (ranibizumab) and Opuviz (aflibercept)—both biosimilars referencing leading treatments for retinal disea
- OneSight EssilorLuxottica Foundation and Vision To Learn Extend Partnership to Expand Vision Care for Children Nationwidehttps://modernod.com/news/onesight-essilorluxottica-foundation-and-vision-to-learn-extend-partnership-to-expand-vision-care-for-children-nationwide/2484209/The OneSight EssilorLuxottica Foundation and Vision To Learn announced a 2-year extension of their 8-year partnership dedicated to providing vision care services to children in need—helping them see clearly and reach their full potential in school and be